[Analysis of Clinical Features of 32 Cases of Adult T-cell Leukemia/Lymphoma in a Single Center]

To analyze the clinical characteristics and prognosis of adult T-cell leukemia/lymphoma (ATLL) patients.

The clinical data of 32 newly diagnosed ATLL patients admitted to our hospital from January 1, 2014, to October 1, 2021 were retrospectively analyzed. The efficacy and the incidence of complications of different chemotherapy regimens were explored, and the factors that may affect patients' prognosis were analyzed.

Among the 32 enrolled ATLL patients, the male-to-female ratio was 1.3:1, and the median age was 53 (range 24-79) years. Of these patients, 21 were of the acute type, 9 of the lymphoma type, and 2 of the chronic type. The main initial manifestations included lymph node enlargement, pulmonary infection, abdominal pain, and rash. Additionally, 28 patients had elevated lactate dehydrogenase (LDH), 14 had hypercalcemia, 20 had bone marrow invasion, and 5 had bone marrow chromosomal abnormalities. 29 patients underwent at least one cycle of chemotherapy, among whom 23 were assessable for efficacy. Of these 23 patients, 9 achieved complete remission (CR) and 4 achieved partial remission (PR), with an objective response rate (ORR) of 56.5%. 4 patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) after chemotherapy. By the end of follow-up, 19 cases had died, 11 cases were lost to follow-up, and 2 cases were alive, with a median survival time (MST) of 10.0 (95%CI: 0.0-20.2) months. Multivariate analysis indicated that sex, age, and white blood cell count (WBC) were independent influencing factors for OS in ATLL patients.

ATLL patients often present with lymph node enlargement, elevated WBC, and elevated LDH at initial diagnosis. Age ≥60 years, and WBC≥10×10⁹/L at initial diagnosis are independent risk factors affecting patient prognosis, while male sex serves as a protective factor for prognosis.